Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 323 | 38 | 285 |
| Samples | 148 | 21 | 127 |
| Peptides | 96 | 15 | 84 |
Function
KLRC3 · Killer cell lectin like receptor C3
Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins, which have been implicated in the regulation of NK cell function. KLRC3 is a member of the NKG2 group which are expressed primarily in natural killer (NK) cells and encodes a family of transmembrane proteins characterized by a type II membrane orientation (extracellular C terminus) and the presence of a C-type lectin domain. The NKG2 gene family is located within the NK complex, a region that contains several C-type lectin genes preferentially expressed on NK cells. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 88 amino-acid changes on canonical ENST00000381903 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KLRC3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KLRC3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 8/612 1% |
| Esophageal Carcinoma | 0/23 0% | 10/769 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Bladder Carcinoma | 2/58 3% | 8/956 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 8/1390 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Melanoma | 0/210 0% | 13/1899 1% |
| Other Solid Cancers | 1/94 1% | 8/1515 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Colorectal Carcinoma | 1/143 1% | 15/3239 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 4/1592 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Gastric Carcinoma | 1/74 1% | 4/1809 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Prostate Carcinoma | 1/13 8% | 3/2105 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 4/2550 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 4/2534 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
Mutation Distribution
Where KLRC3 is mutated · all tissues, split by cell line vs tissue
How many mutations in KLRC3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 52 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 323 mutations in KLRC3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|